SITC presents annual awards highlighting achievements in cancer immunotherapy
Click Here to Manage Email Alerts
The Society for Immunotherapy of Cancer will honor several recipients with its annual awards, presented this week during its 36th Annual Meeting & Pre-Conference Programs.
Among the recipients are Michael T. Lotze, MD, chief cellular therapy officer of Nurix Therapeutics and professor of surgery, immunology and bioengineering at the University of Pittsburgh School of Medicine, who will receive SITC’s Lifetime Achievement Award.
Lotze is regarded as an expert in tumor immunology, with research interests in cellular therapy using dendritic cells and natural killer cells. He is also chair of the Alliance for Cancer Gene Therapy (ACGT) Scientific Advisory Council, which reviews and monitors cancer cell and gene therapy research selected for funding by the organization.
Other annual award recipients include:
- 2021 Pedro J. Romero Service to JITC Award, presented to James L. Gulley, MD, PhD, FACP, NCI/NIH;
- 2021 Tara Withington Public Service Award, presented to Margaret Foti, PhD, MD (hc), American Association for Cancer Research;
- 2021 Team Science Award, presented to Silvia Formenti, MD; Sandra Demaria, MD, and team, Weill Cornell Medicine; and
- 2022 Richard V. Smalley Memorial Award, presented to Zelig Eshhar, MD, Weizmann Institute of Science and the Tel Aviv Sourasky Medical Center.
“SITC is proud to recognize these outstanding individuals from the cancer immunology and immunotherapy community,” Patrick Hwu, MD, CEO of Moffit Cancer Center and president of SITC, said in a society-issued press release. “The annual awards represent the growing prestige of our society and our field thanks to the work of these incredible honorees on behalf of patients.”
Click Here to Manage Email Alerts